GPCR Monoclonal Ab

As the largest human membrane protein family responsible for functions such as sensory regulations and cellular responses, GPCRs are considered one of the most valuable drug targets in the pharmaceutical industry. Abnova has developed a robust, reliable, and cost-effective high throughput platform of proteoliposome reconstitution system and monoclonal antibody (mAb) production targeting GPCRs to overcome the hindrance of lacking suitable antigens for producing high-quality mAbs.

By optimizing cell-free protein synthesis in the presence of liposomes and a purification process via discontinuous sucrose density gradient centrifugation, soluble reconstituted GPCR proteoliposome antigens are synthesized. Abnova’s exclusive techniques in manufacturing proprietary bioreagents allow us to not only produce GPCR proteoliposomes, amenable to functional analysis but also generate customized mAbs with sensitivity, specificity, and wide dynamic range. A high successful rate on customized GPCR mAbs has also expanded our field to deliver mAbs targeting various membrane proteins as well.